Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

X4 Pharmaceuticals, Inc. - Common Stock (NQ:XFOR)

3.750 -0.560 (-12.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about X4 Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For March 25, 2025
Via Benzinga
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Recap: X4 Pharmaceuticals Q4 Earnings
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Earnings Preview For X4 Pharmaceuticals
Via Benzinga
Top 3 Health Care Stocks That May Rocket Higher In April
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session.
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
X4 Pharmaceuticals's Earnings Outlook
Via Benzinga
Recap: X4 Pharmaceuticals Q3 Earnings
Via Benzinga
Earnings Outlook For X4 Pharmaceuticals
Via Benzinga
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic this morning and we've got traders covered with all of the news behind these movements on Thursday! 
Via InvestorPlace
XFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024
XFOR stock results show that X4 Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder
FDA approves Xolremdi capsules for WHIM syndrome, boosting neutrophil & lymphocyte counts. First therapy for this rare immunodeficiency disorder. Potential sales forecasted at $54.6M in 2024, rising to... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
XFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023
XFOR stock results show that X4 Pharmaceuticals beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of bluebird bio, Inc. (NASDAQ: BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the... 
Via Benzinga
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Shares of Green Giant Inc. (NASDAQ: GGE) fell sharply in pre-market trading after announcing a proposed public offering. Green Giant shares dipped 37.1% to $0.1599 in pre-market trading. Here are some... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning! 
Via InvestorPlace
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Investors are on the hunt for undervalued, underfollowed and emerging stocks, and retail traders have countless methods at their disposal to uncover new information. For some, this may be... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.